Journal of the Korean Applied Science and Technology (한국응용과학기술학회지)

The Korean Society of Applied Science and Technology (한국응용과학기술학회)
권호 표지
DOI QR코드

DOI QR Code

Synthesis of New Benzaminoquinoline Derivatives with Antiproliferative Activity against Melanoma Cell Line

흑색종 세포증식 저해효능의 새로운 Benzaminoquinoline 유도체의 합성

  • Yoo, Kyung-Ho (Biomaterials Research Center, Korea Institute of Science and Technology) ;
  • Nam, Bong-Soo (Biomaterials Research Center, Korea Institute of Science and Technology)
  • 유경호 (한국과학기술연구원 바이오소재연구센터) ;
  • 남봉수 (한국과학기술연구원 바이오소재연구센터)
  • Published : 2009.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Melanoma is the most serious type of skin cancer as a malignant tumor of melanocytes. In this work, the syntheses of a novel series of benzaminoquinoline derivatives 1a-c and their antiproliferative activities against A375 human melanoma cell line were described. All the compounds ($IC_{50}=0.78-1.02{\mu}M$) showed superior antiproliferative activities to Sorafenib ($IC_{50}=5.58{\mu}M$) as a reference compound. These results suggested that benzaminoquinoline derivatives have potentials as a therapeutic agent for the treatment for melanoma.

Keywords

References

  1. B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J Clin Invest., 105, 3 (2000)
  2. D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZDI839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin Oneal., 29 (Supplement 4), 37 (2002)
  3. R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, ]. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non - Small-Cell Lung Cancer, J Clin Oneal., 22, 3238 (2004) https://doi.org/10.1200/JCO.2004.11.057
  4. C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian, W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and Interdisciplinary Consense-based C'xerman Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007) https://doi.org/10.1097/CMR.0b013e3282f05039
  5. J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M. Mihm, Jr., Molecular Diagnostics In Melanoma, J Am Arod Dermatol., 52, 743 (2005) https://doi.org/10.1016/j.jaad.2004.08.034
  6. A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curro Oneal. Rep., 2, 322 (2000) https://doi.org/10.1007/s11912-000-0025-9
  7. M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J Clin Oneal., 18, 158 (2008)
  8. A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, Bd-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J Clin Oneal., 24, 4738 (2006) https://doi.org/10.1200/JCO.2006.06.0483
  9. D. H. Lawson, Choices in Adjuvant Therapy of Melanoma, Cancer Control, 12, 236 (2005)
  10. S. A. Rosenburg, M. T. Lotze, J. c. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989) https://doi.org/10.1097/00000658-198910000-00008
  11. M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993, J. Clin. Oncol., 17, 2105 (1999) https://doi.org/10.1200/JCO.1999.17.7.2105
  12. C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995)
  13. L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, Dacarbazine-based Chemotherapy for Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000)
  14. W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E. Hynes, L. F. Hutchins, and ]. R. Pancoast, Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma, Am J. Clin. Oncol., 16, 359 (1993) https://doi.org/10.1097/00000421-199308000-00018
  15. A. L. Ruchelman, J. E. Kenigan, T. - K. Li, N. Zhou, A. Liu, L. F. Liu, E. J. LaVoie, Nitro and Amino Substitution within the A-ring of 5H-S,9- dimethoxy-5- (2-N ,N -dimethylaminoethyl) dibenzo[c,h] [l,6]naphthyridin -6-ones: Influence on Topoisomerase I-Targeting Activity and Cytotoxicity, Bioorg. Med Chem, 12, 3731 (2004) https://doi.org/10.1016/j.bmc.2004.03.076
  16. S. A. Laufer, D. M. Domeyer, T. R. F. Scior, W. Albrecht, D. R. ]. Hauser, Synthesis and Biological Testing of Purine Derivatives as Potential A TP-competitive Kinase Inhibitors, J. Med Chem, 48, 710 (2005) https://doi.org/10.1021/jm0408767
  17. L. V. Dubey and I. V. Dubey, Side Reactions of Onium Coupling Reagents BOP and HBTU in the Synthesis of Silica Polymer Supports, Ukr. Bioorg. Acta, 1, 13 (2005)
  18. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer Ther., 7, 3129 (2008) https://doi.org/10.1158/1535-7163.MCT-08-0013